Daniel Molin

• Övergaard, Ninja; Lia, Kjersti; Collin, Jeremia; Asdahl, Peter H.; Wikman, Per & Glimelius, Ingrid [Vis alle 16 forfattere av denne artikkelen] (2026). AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma. Blood Advances. ISSN 2473-9529. 10(14), s. 4889–4897. doi: 10.1182/bloodadvances.2025018954. Fulltekst i vitenarkiv
• Lia, Kjersti; Jørgensen, Rasmus Rask Kragh; Wikman, Per; Wold, Bente Loftum; Övergaard, Ninja & Fluge, Øystein [Vis alle 12 forfattere av denne artikkelen] (2025). A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma. Haematologica. ISSN 0390-6078. 110(10), s. 2356–2366. doi: 10.3324/haematol.2025.287509. Fulltekst i vitenarkiv Vis sammendrag

  Older patients with classical Hodgkin lymphoma (cHL) have lower tolerance and inferior outcomes after standard chemotherapy regimens. To identify patient-derived indicators of frailty associated with outcome, we retrospectively analyzed patient and disease characteristics, treatment and outcome in a Norwegian population-based cohort of older (≥60 years) patients with cHL diagnosed 2000-2015. We included 279 patients (median age 69 years, range 60-90) treated with curative intent, defined as any typical cHL regimen with ≥50% standard doxorubicin dose in the first cycle. Treatment-related mortality was 8%, median progression-free (PFS) and overall survival (OS) were 7.1 years (95% confidence interval [CI] 5.0-9.3) and 8.7 years (95%CI 7.0-10.4), respectively, in the Norwegian cohort. Multivariable analyses identified patient-derived prognostic factors working independently of stage, histology and international prognostic score. We derived a frailty index ranging from 0-3 with one point each for age ≥70 years, Eastern Cooperative Oncology Group status ≥2 and a Cumulative illness rating scale in geriatrics score ≥8. Patients were categorized as fit (score 0, 34% of patients), unfit (score 1-2, 60%) and frail (score 3, 7%), with 5-year PFS of 74%, 49% and 11%, and 5-year OS of 86%, 52%, and 22% respectively. The proposed frailty score was validated in an external cohort of 792 similarly selected patients from the Swedish Lymphoma Register, where comorbidities were scored based on the Charlson comorbidity index (0-2 versus 3 or higher). In this comprehensive study, we develop a frailty score for elderly cHL patients to inform clinical decisions and prospective trials evaluating selective therapies for older patients.

• Borchmann, Peter; Ferdinandus, Justin; Schneider, Gundolf; Moccia, Alden; Greil, Richard & Hertzberg, Mark [Vis alle 50 forfattere av denne artikkelen] (2024). Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. The Lancet. ISSN 0140-6736. 404(10450), s. 341–352. doi: 10.1016/S0140-6736(24)01315-1. Fulltekst i vitenarkiv
• Nikkarinen, Anna; Lokhande, Lavanya; Amini, Rose-Marie; Jerkeman, Mats; Porwit, Anna & Molin, Daniel [Vis alle 14 forfattere av denne artikkelen] (2023). Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma. Blood Advances. ISSN 2473-9529. 7(18), s. 5304–5313. doi: 10.1182/bloodadvances.2023010052. Fulltekst i vitenarkiv Vis sammendrag

  The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.

• Luminari, Stefano; Fosså, Alexander; Trotman, Judith; Molin, Daniel; D'Amore, Francesco & Enblad, Gunilla [Vis alle 12 forfattere av denne artikkelen] (2023). Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of Clinical Oncology. ISSN 0732-183X. 42(1), s. 13–18. doi: 10.1200/JCO.23.01177. Fulltekst i vitenarkiv
• Fontaine, Margaux A. C.; Jin, Han; Gagliardi, Mick; Rousch, Mat; Wijnands, Erwin & Stoll, Monika [Vis alle 23 forfattere av denne artikkelen] (2022). Blood Milieu in Acute Myocardial Infarction Reprograms Human Macrophages for Trauma Repair. Advanced Science. s. 1–14. doi: 10.1002/advs.202203053. Fulltekst i vitenarkiv Vis sammendrag

  Acute myocardial infarction (AMI) is accompanied by a systemic trauma response that impacts the whole body, including blood. This study addresses whether macrophages, key players in trauma repair, sense and respond to these changes. For this, healthy human monocyte-derived macrophages are exposed to 20% human AMI (n = 50) or control (n = 20) serum and analyzed by transcriptional and multiparameter functional screening followed by network-guided data interpretation and drug repurposing. Results are validated in an independent cohort at functional level (n = 47 AMI, n = 25 control) and in a public dataset. AMI serum exposure results in an overt AMI signature, enriched in debris cleaning, mitosis, and immune pathways. Moreover, gene networks associated with AMI and with poor clinical prognosis in AMI are identified. Network-guided drug screening on the latter unveils prostaglandin E2 (PGE2) signaling as target for clinical intervention in detrimental macrophage imprinting during AMI trauma healing. The results demonstrate pronounced context-induced macrophage reprogramming by the AMI systemic environment, to a degree decisive for patient prognosis. This offers new opportunities for targeted intervention and optimized cardiovascular disease risk management.

• Jakobsen, Lasse Hjort; Ellin, Fredrik; Smeland, Knut Bjøro; Wästerlid, Tove; Christensen, Jacob Haaber & Jørgensen, Judit Mészáros [Vis alle 24 forfattere av denne artikkelen] (2020). Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients. British Journal of Haematology. ISSN 0007-1048. 189(4), s. 661–671. doi: 10.1111/bjh.16425. Fulltekst i vitenarkiv Vis sammendrag

  Non‐endemic Burkitt lymphoma (BL) is a rare germinal centre B‐cell‐derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic‐based and population‐based lymphoma registries from six countries were used to identify 264 real‐world patients. The median age was 47 years and the majority had advanced‐stage disease and elevated LDH. Treatment protocols were R‐CODOX‐M/IVAC (47%), R‐hyper‐CVAD (16%), DA‐EPOCH‐R (11%), R‐BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two‐year overall survival and event‐free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two‐year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post‐remission event‐free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: −0·7 to 2) months. In conclusion, real‐world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow‐up strategies with increased focus on survivorship and less focus on routine disease surveillance.

• Lagerlöf, Ingemar; Holte, Harald; Glimelius, Ingrid; Björkholm, Magnus; Enblad, Gunilla & Erlanson, Martin [Vis alle 20 forfattere av denne artikkelen] (2019). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. ISSN 0007-1048. s. 1–7. doi: 10.1111/bjh.16232. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Lia, Kjersti; Jørgensen, Rasmus Rask Kragh; Wikman, Per; Wold, Bente; Övergaard, Ninja & Fluge, Øystein [Vis alle 12 forfattere av denne artikkelen] (2025). Response to Comment on: “A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma”. Haematologica. ISSN 0390-6078. 110(11), s. 2866–2867. doi: 10.3324/haematol.2025.288284. Fulltekst i vitenarkiv
• Fosså, Alexander; Molin, Daniel; Bröckelmann, Paul J.; Schneider, Gundolf; Schnetzke, Ulf & Linderoth, Johan [Vis alle 14 forfattere av denne artikkelen] (2025). Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial. HemaSphere. 9(3). doi: 10.1002/hem3.70099. Fulltekst i vitenarkiv
• Molin, Daniel (2024). From Petrol Stations to Charging Networks. Fulltekst i vitenarkiv

Se alle arbeider i NVA